Denver Arthritis Clinic | Denver, CO

Research site

(Unclaimed)

Location

200 Spruce Street Suite 100, Denver, Colorado, United States of America

Site insights

Top conditions

Top treatments

Upadacitinib

Methotrexate

ABT-494

MTX

Adalimumab

Olokizumab

Deucravacitinib

ABBV-154

Dazodalibep

Tocilizumab

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

17 of 50 total trials

Locations recently updated

A Safety and Efficacy Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-Severe Symptom State

Primary Objective:To evaluate the effect of dazodalibep on patient-reported symptoms of SS in participants with moderate-to-severe symptom stateSecon...

Enrolling

Sjögren's Syndrome (SS)

Drug: Dazodalibep

Drug: Placebo

A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) (KEEPsAKE2)

The purpose of this study is to evaluate the safety and efficacy of risankizumab in adults with moderately to severely active psoriatic arthritis (Ps...

Active, not recruiting

Psoriatic Arthritis (PsA)

Biological: Placebo

Biological: Risankizumab

A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) (SELECT - PsA 1)

This study includes two periods. The main objective of Period 1 is to compare the efficacy of upadacitinib 15 mg once daily (QD) and 30 mg QD versus...

Active, not recruiting

Psoriatic Arthritis

Drug: Adalimumab

Drug: Placebo to Adalimumab

A Study Comparing Upadacitinib (ABT-494) to Placebo in Participants With Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug (bDMARD) (SELECT - PsA 2)

The study objectives of Period 1 are to compare the efficacy, safety, and tolerability of upadacitinib 15 mg once daily (QD) and 30 mg QD versus plac...

Active, not recruiting

Psoriatic Arthritis

Drug: Placebo

Drug: Upadacitinib

A Study of Peresolimab (LY3462817) in Participants With Moderately-to-Severely Active Rheumatoid Arthritis (RESOLUTION-1)

The main purpose of this study is to assess the safety and efficacy of peresolimab in adult participants with moderately-to-severely active rheumatoi...

Active, not recruiting

Joint Diseases

Arthritis

Drug: Peresolimab

Drug: Placebo

A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE) (POETYK SLE-1)

The purpose of this study is to evaluate the effectiveness and safety of deucravacitinib compared with placebo in an active moderate to severe System...

Enrolling

Systemic Lupus Erythematosus

Other: Placebo

Drug: Deucravacitinib

A Study to Assess the Efficacy and Safety of BIIB059 (Litifilimab) in Participants With Active Subacute Cutaneous Lupus Erythematosus (SCLE) and/or Chronic Cutaneous Lupus Erythematosus (CCLE) With or Without Systemic Manifestations and Refractory and/or Intolerant to Antimalarial Therapy (AMETHYST)

The primary objectives of the study are to evaluate the efficacy of BIIB059 (litifilimab) compared with placebo in reducing skin disease activity mea...

Enrolling

Subacute Cutaneous Lupus Erythematosus

Chronic Cutaneous Lupus Erythematosus

Drug: BIIB059 (litifilimab)

Drug: Placebo

A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs

The purpose of this study is to evaluate the efficacy and safety of deucravacitinib versus placebo in participants with active psoriatic arthritis wh...

Active, not recruiting

Psoriatic Arthritis

Drug: Deucravacitinib

Other: Placebo

A Study to Evaluate Efficacy and Safety of Upadacitinib in Adults With Axial Spondyloarthritis (SELECT-AXIS 2)

This protocol includes 2 standalone studies with randomization, data collection, analysis and reporting conducted independently.The main objectives o...

Active, not recruiting

Spondyloarthritis

Drug: Placebo

Drug: Upadacitinib

A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease Activity

Primary Objective:To evaluate the effect of dazodalibep on systemic manifestations of Sjögren's Syndrome (SS) in participants with moderate-to-severe...

Enrolling

Sjogren's Syndrome

Drug: Dazodalibep

Drug: Placebo

A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren's Syndrome (POETYK SjS-1)

The purpose of this study is to assess the safety and efficacy of two doses of Deucravacitinib in adult participants with Active Sjögren's Syndrome.

Enrolling

Sjögren's Syndrome

Other: Placebo

Drug: Deucravacitinib

A Study to Evaluate the Safety and Efficacy of Upadacitinib in Participants With Giant Cell Arteritis (SELECT-GCA)

This study consists of two periods. The objective of Period 1 is to evaluate the efficacy of upadacitinib in combination with a 26-week corticosteroi...

Active, not recruiting

Giant Cell Arteritis (GCA)

Drug: Upadacitinib

Other: Placebo

A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy. (ALKIVIA)

This study's purpose is to measure the treatment response from efgartigimod PH20 SC compared with placebo in participants with Idiopathic Inflammator...

Enrolling

Dermatomyositis

Myositis

Biological: EFG PH20 SC

Other: PBO

A Trial to Investigate the Non-inferiority of Pegloticase Administered Every 4 Weeks (Q4W) With MTX Compared With Every 2 Weeks (Q2W) With MTX in Participants With Uncontrolled Refractory Gout

The study consists of 24-week double-blind trial to evaluate the non-inferiority of the efficacy and safety of pegloticase Q4W with MTX versus peglot...

Enrolling

Gout

Drug: Methotrexate

Biological: Pegloticase

Efficacy And Safety Of MK-6194 In Adult Participants With Systemic Lupus Erythematosus (MK-6194-006)

The purpose of this study is to evaluate the efficacy and safety of MK-6194 in adult participants with Systemic Lupus Erythematosus. The primary hypo...

Enrolling

Systemic Lupus Erythematosus

Biological: MK-6194

Biological: Placebo

Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE)

Systemic Lupus Erythematosus (SLE) is an immune-mediated disease associated with inflammation of multiple organ systems. This study will assess how s...

Enrolling

Systemic Lupus Erythematosus

Drug: Upadacitinib

Drug: Placebo

Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH)

Rheumatoid Arthritis (RA) is a chronic inflammatory disease causing pain, stiffness, swelling and loss of joint function. This study will assess how...

Enrolling

Rheumatoid Arthritis

Drug: Adalimumab

Drug: Upadacitinib